Tag: Roche

Roche and AC Immune Stop Trials of Alzheimer’s Drug

Roche and AC Immune have discontinued phase III trials of their Alzheimer’s disease drug crenezumab after an interim analysis indicated it would not hit its primary endpoint. Crenezumab is an anti-...

Basilea Collaborates with Roche to Explore Urothelial Cancer Drugs

ArQule, Inc.’s partner, Basilea Pharmaceutica Ltd., announced that it entered into a collaboration with Roche to explore a combination of derazantinib (BAL087) and Roche’s PD-L1-blocking immune-checkp...

Roche Has to Wait for FDA Decision for NSCLC Drug

Roche will wait until September 2019 for the FDA’s decision, before it can combine Tecentriq with Abraxane and carboplatin for the first-line treatment of lung cancer patients, who don’t have EGFR or ...

Big Pharma’s Experts Go to Biotech

Three more big pharma R&D names have made the jump to biotech as Voyager Therapeutics, ImmunSYS and Immunocore announce they have appointed former execs from Roche, Novartis and AstraZeneca. Vo...

Phoenix and Roche to Develop Diagnostic for TNBC

Phoenix Molecular Designs and Roche partnered on Wednesday to develop a molecular diagnostic to help stratify triple-negative breast cancer patients. Roche will develop an assay to detect activatio...

MilliporeSigma and Roche Prolong Collaboration

MilliporeSigma and Roche have agreed to renew their current distribution agreement for the Biochemical Reagents and Kapa Biosystems product portfolios, as well as select qPCR & Nucleic Acid Purifi...

Adaptive and Genentech to Develop Treatment of Cancers

Adaptive Biotechnologies, an immune-driven medicine company, today announced that it will enter into a worldwide collaboration and license agreement with Genentech, a member of the Roche Group, to dev...

EMA Grants Roche’s Drug PRIME Status

Roche is hoping to challenge Biogen with a new treatment for the rare muscle wasting disease spinal muscular atrophy – and the plans just got a boost after European regulators gave it special priority...

MMCC aims to catalyze transformational Change in Microbiology Testing

Attending Pharmig 2018, AstraZeneca's Karen Capper and GSK's Paul J Newby unveiled details of the Microbiology Modernisation Cross-industry Consortium (MMCC), an initiative that has been in the making...

Halozyme licenses its drug delivery technology to Roche

drug-delivery-tech
Halozyme Therapeutics, a biotechnology company developing novel oncology and drug-delivery therapies, announced that it has licensed its ENHANZE® drug-delivery technology to Roche.

Roche and SQZ Biotech extend collaboration in stem cell therapy

stem-cell
SQZ Biotechnologies (SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, announced the expansion of its collaboration with Roche in cellular therapy.

Russian and Swiss scientists to cooperate on personalized medicine

personalized-medicine
The 5th Swiss-Russian Health Forum welcomed prominent political leaders, representatives of various agencies & institutions, scientists and medical doctors at the 5th Swiss-Russian Health Forum.

The 5th Swiss-Russian Health Forum has been opened in Moscow

medical-devices
The Forum agenda is Medical Education, Translational Medicine, Digital Health: meeting the challenges of the Future Today.

PureTech Health entered into a multiyear collaboration with Roche

microscope
PureTech Health, a clinical-stage biopharmaceutical company developing novel medicines focused on the Brain-Immune-Gut (BIG) Axis, announced that it has entered into a multiyear collaboration with Roche.

Kymab and Roche entered a clinical trial agreement

clinical trials
Kymab announced Roche will provide its PD-L1 blocking antibody atezolizumab for use in combination with Kymab's lead investigational anti-ICOS antibody therapy KY1044 in Kymab's upcoming Phase I/II clinical studies.

Roche pays $2.4 billion to acquire Foundation Medicine

roche
Roche and Foundation Medicine (USA) entered into a definitive merger agreement for Roche to acquire the outstanding shares of FMI's common stock not already owned by Roche with a total transaction value of $2.4 billion.